Werewolf Therapeutics
HOWL
35 hedge funds and large institutions have $51.1M invested in Werewolf Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 3 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.55% less ownership
Funds ownership: 67.52% → 66.97% (-0.55%)
3% less funds holding
Funds holding: 36 → 35 (-1)
30% less capital invested
Capital invested by funds: $73.3M → $51.1M (-$22.2M)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$701K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$231K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$92.4K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$27.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.08M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$419K |
| 3 |
Two Sigma Investments
New York
|
-$50.4K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$12.1K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.41K |
HOWL Hedge Fund Activity: Q3 2023 in Review
35 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q3 2023, worth a combined $51.1M — down 30% from $73.3M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of HOWL and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 11 added.
The largest buyer was PFM Health Sciences, adding an estimated $701K. The largest seller was Millennium Management, cutting an estimated $1.08M.
- 35 institutional investors held Werewolf Therapeutics (HOWL) as of Q3 2023, down from 36 in Q2 2023.
- Funds reported $51.1M of Werewolf Therapeutics stock for Q3 2023, down 30% quarter-over-quarter.
- 2 funds opened new Werewolf Therapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest Werewolf Therapeutics buyer in Q3 2023 was PFM Health Sciences, an estimated $701K added.
- The largest Werewolf Therapeutics seller in Q3 2023 was Millennium Management, an estimated $1.08M sold.
Based on aggregated 13F filings for Q3 2023.